Arthritis Pain

Arthritis Pain Treatment | Ketamine Therapy for Arthritis Pain

Arthritis pain changes over time in a way that most people do not expect when they first receive the diagnosis. What starts as stiffness and intermittent joint pain becomes a constant background presence that reshapes how you move, what you do, and how much of yourself you reserve just for managing it. Medications help, then help less. Procedures provide relief that lasts months before it fades. And at some point the clinical conversation shifts from controlling the condition to managing a pain state that has become partly independent of the underlying joint disease.

Arthritis pain ketamine therapy is one option that some patients with refractory arthritis-related pain eventually consider, usually after that shift has already occurred. Allay Health and Wellness offers arthritis pain ketamine therapy in Palm Beach Gardens, Florida, as an off-label clinical service for adults whose arthritis pain has not been adequately controlled by established treatments. This page explains why arthritis pain becomes difficult to manage over time, where arthritis pain ketamine therapy fits in that progression, what the evidence supports, and who may be a candidate for evaluation.

Understanding Arthritis Pain at a Clinical Level

Arthritis is a category that includes more than a hundred conditions characterized by joint inflammation, pain, and progressive damage. Two major types are most relevant here:

• Osteoarthritis is the most common form, characterized by cartilage breakdown, subchondral bone changes, and joint deformity. Primarily degenerative, though inflammation plays a meaningful role in later stages. Pain is initially nociceptive but increasingly involves central sensitization as the condition progresses.
• Rheumatoid arthritis is an autoimmune inflammatory arthritis in which the immune system attacks the synovial lining of joints, producing systemic inflammation and joint destruction. Disease-modifying treatments have substantially improved RA outcomes, but a significant proportion of patients still experience inadequately controlled pain despite disease control.

The Arthritis Foundation documents that arthritis is one of the most common causes of chronic pain and disability in the United States, affecting tens of millions of adults across all types. The feature that makes arthritis pain particularly difficult over time is the transition from peripheral nociceptive pain to a pain state that involves significant central sensitization. Once central sensitization is established, pain may persist or amplify even when joint inflammation is well controlled pharmacologically. This is the clinical context in which arthritis pain ketamine therapy becomes a rational consideration.

First-Line Treatments for Arthritis Pain

Arthritis pain ketamine therapy is not where treatment starts, and any page that does not say so first is not serving patients well. For osteoarthritis, first-line treatment includes acetaminophen and topical NSAIDs for mild to moderate pain, oral NSAIDs for more significant pain, intra-articular corticosteroid injections, and hyaluronic acid injections for knee OA in appropriate patients. Physical therapy, weight management, and activity modification have strong evidence. For end-stage joint disease, arthroplasty can provide dramatic pain relief and should be considered before off-label infusion therapy.

For rheumatoid arthritis, the primary treatment priority is disease control through DMARDs including methotrexate, biologics, and JAK inhibitors, alongside NSAIDs and low-dose corticosteroids for symptom management. The American College of Rheumatology maintains clinical guidelines on arthritis management that represent the standard of care before any off-label approaches are considered. When disease is controlled, but pain persists, the clinical picture has shifted toward centralized pain, which is where arthritis pain ketamine therapy may have a role.

Why Arthritis Pain Becomes Centralized Over Time

This mechanism helps explain why arthritis pain ketamine therapy may become a consideration for some patients whose pain persists despite appropriate management of their underlying joint disease. In the earlier stages of arthritis, pain is often primarily nociceptive. Damaged or inflamed joint tissue activates nociceptors, which transmit pain signals through the nervous system. Treatments directed at inflammation, joint disease, and other underlying causes remain central to care.

Over time, particularly with persistent pain, repeated nociceptive input may contribute to central sensitization. The nervous system can become increasingly responsive to pain signals, and NMDA receptor activity is among the mechanisms involved in this process. When central sensitization develops, pain may become disproportionate to structural findings or persist despite improved control of inflammation. Patients may also experience widespread tenderness, allodynia, or hyperalgesia. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, arthritis includes conditions affecting joints and surrounding tissues and can produce persistent pain and functional limitations. Understanding the source of continuing pain remains important because arthritis-related pain can involve more than one mechanism.

Why Ketamine May Be Relevant to Centralized Pain

Ketamine acts as an NMDA receptor antagonist, providing a biological rationale for investigating its effects on central sensitization and altered pain processing. This mechanism helps distinguish arthritis pain ketamine therapy from treatments directed primarily at inflammation or structural joint disease. However, a mechanistic rationale does not establish effectiveness for arthritis pain, and IV ketamine remains an off-label treatment whose potential role requires individualized evaluation.

The glutamatergic and NMDA receptor activity involved here also helps explain how ketamine works within neural pathways associated with anxiety and altered sensory processing. From a pain perspective, the broader clinical use of ketamine for chronic pain provides additional context for why NMDA receptor modulation has been investigated across conditions involving neuropathic or centralized pain.

The Off-Label Reality

Arthritis pain ketamine therapy is an off-label use. This must be stated clearly and without qualification. The FDA has not approved IV ketamine for arthritis pain, for osteoarthritis, for rheumatoid arthritis, or for any pain condition. Ketamine’s only FDA-approved indication is as a general anesthetic. Spravato (esketamine) is not approved for any pain condition. Its approved indications are treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is not used at Allay Health and Wellness for arthritis or any pain presentation.

Off-label prescribing by a licensed clinician is legal and routine across medicine. Many analgesic and anti-inflammatory treatments in clinical use were adopted via off-label practice before formal trial data was complete. Patients pursuing arthritis pain ketamine therapy should understand the regulatory status, the current evidence base, and realistic expectations before evaluation begins. We do not present this as an established treatment. We present it as a clinically rational off-label option for a specific subset of patients with refractory, centralized arthritis pain.

Who May Be a Candidate for Arthritis Pain Ketamine Therapy

A clinical evaluation at Allay Health & Wellness determines whether arthritis pain ketamine therapy may be appropriate. Potential candidates generally have persistent arthritis-related pain despite established treatment and require an individualized review of their pain characteristics, treatment history, medical conditions, and current disease management.

• Documented arthritis diagnosis with persistent pain despite appropriate first-line treatments;
• Centralized pain features such as widespread tenderness, allodynia, pain disproportionate to imaging findings, or continued pain despite adequate disease control;
• Inadequate response to at least two appropriate treatments for the diagnosed type of arthritis;
• Willingness to continue disease management with a rheumatologist, orthopedic specialist, or other existing provider while pursuing arthritis pain ketamine therapy;
• No medical or psychiatric contraindications that would make treatment inappropriate, including uncontrolled hypertension, unstable cardiovascular conditions, or active psychosis;
• Substance use history reviewed individually because ketamine is a federally regulated Schedule III controlled substance and requires appropriate clinical assessment;
• Adults age 18 or older, as Allay Health & Wellness exclusively treats adult patients.

Our ketamine therapy FAQ addresses common questions, while broader ketamine therapy eligibility depends on each patient’s medical history and clinical evaluation.

What the Evidence Shows

The direct evidence base for arthritis pain ketamine therapy as a specific indication is limited. Most published data on ketamine in chronic pain comes from mixed chronic pain populations, neuropathic pain trials, and centralized pain conditions such as complex regional pain syndrome and fibromyalgia, with arthritis pain as a secondary or incidentally included presentation rather than a primary target.

What the broader literature establishes, and what is applicable here through mechanistic inference, is that IV ketamine can produce significant reductions in pain intensity in patients with centralized pain states and central sensitization as a primary driver of their pain. The Pain Medicine review of ketamine in chronic pain conditions found analgesic effects particularly in centralized and neuropathic presentations, with benefit more pronounced in patients with documented central sensitization features. For arthritis patients specifically, the most clinically relevant subset is those who show central sensitization features: widespread tenderness beyond the affected joints, pain that is disproportionate to imaging findings, allodynia, and persistence despite adequate disease control. In this group, the mechanistic argument for arthritis pain ketamine therapy is most coherent, and the evidence base from broader centralized pain research is most applicable.

Arthritis Pain, Mood, and the Amplification Dynamic

Chronic arthritis pain and depression frequently occur together, creating a bidirectional relationship that matters when considering arthritis pain ketamine therapy. Persistent pain can contribute to depression through disrupted sleep, reduced mobility, functional limitations, and the psychological burden of living with ongoing symptoms. Depression may also intensify the experience of pain through changes in pain processing, reduced activity, sleep disruption, and other factors associated with greater pain-related disability. For patients experiencing arthritis pain alongside significant depression, both conditions deserve appropriate evaluation rather than assuming that improvement in one will automatically resolve the other. When depressive symptoms are clinically significant, ketamine therapy for depression may become a separate part of the treatment discussion, while broader mental health care can address anxiety, depression, and other psychiatric concerns that may coexist with chronic pain.

Daniel Cartledge, M.D., our clinical consultant, is double board-certified in pain management and physical medicine and rehabilitation, bringing relevant experience to cases where arthritis pain, physical function, and psychiatric symptoms overlap. Patients can also review the credentials of the broader Allay Health & Wellness clinical team when considering their care options.

What Arthritis Pain Ketamine Therapy Involves at Allay

Every patient considering arthritis pain ketamine therapy at Allay Health & Wellness begins with an individualized clinical evaluation. Our team reviews your arthritis history, current disease management, previous treatments, and overall health before determining whether off-label IV ketamine may be appropriate.

• Evaluation: Intake covers your arthritis diagnosis and type, disease control, previous treatments with doses and durations, current medications including DMARDs and biologics, cardiovascular health, substance use history, and co-occurring psychiatric conditions. We also review your current rheumatology or orthopedic care and coordinate with existing providers rather than replacing them. No referral is required. Bring your available clinical records.
• The Sessions: IV ketamine is administered slowly through an intravenous line in a private, monitored room. A licensed clinician remains present and monitors vital signs throughout treatment. Pain protocols may differ from psychiatric protocols in duration and scheduling. For arthritis pain ketamine therapy, the number and frequency of infusions depend on your clinical presentation and response. During consultation, we also discuss how many ketamine therapy sessions may be needed and set realistic expectations about the treatment course.
• After Sessions: You may not drive after an infusion. A responsible adult must arrange transportation home, and you should follow the individualized post-treatment instructions provided by your clinical team.

Risks and Side Effects of Arthritis Pain Ketamine Therapy

Every patient evaluated for arthritis pain ketamine therapy receives a clear explanation of potential risks, side effects, and treatment limitations before anything is scheduled. Ketamine can cause temporary dissociation, including changes in perception, awareness, time, space, or sense of self, and clinical staff monitor these effects throughout treatment. Sedation can also occur, so patients may not drive after an infusion and must arrange transportation home.

Temporary increases in blood pressure and heart rate can occur and are monitored before, during, and after every session. Nausea may occur during pain-management infusions, and clinicians may consider preventive anti-nausea medication based on individual history and clinical judgment. Some patients may also experience vivid perceptual or emotional changes during treatment, with clinical staff remaining present throughout the infusion.

Ketamine is a federally regulated Schedule III controlled substance, making the question of whether ketamine can be addictive an important part of informed treatment discussions. Dependency and misuse risks are reviewed during evaluation. No outcome from arthritis pain ketamine therapy is guaranteed. Individual responses vary, and evidence specifically supporting ketamine for arthritis pain remains limited.

FAQs about Arthritis Pain Ketamine Therapy

1. Is ketamine FDA-approved for arthritis pain?
   No. Arthritis pain ketamine therapy is an off-label use. The FDA has not approved IV ketamine for arthritis pain or any pain condition. Spravato is not approved for pain. Established treatments appropriate to the specific type of arthritis should generally be considered before off-label treatment options.
2. My rheumatoid arthritis is controlled, but I still have pain. Could ketamine be relevant?
   Possibly. Some patients continue to experience persistent pain even when inflammatory disease activity is well controlled. Central sensitization or other pain mechanisms may contribute in certain cases. Arthritis pain ketamine therapy may be considered for selected patients after an individualized evaluation, but ketamine does not treat the underlying inflammatory disease, and improvement cannot be predicted or guaranteed.
3. Will ketamine interfere with my current arthritis medications?
   Your complete medication list, including DMARDs, biologics, corticosteroids, NSAIDs, and other prescriptions, is reviewed during intake. Medication interactions and individual medical risks are assessed before treatment. Do not stop or change any arthritis medication without guidance from the clinician who manages your condition.
4. Does insurance cover arthritis pain ketamine therapy?
   Off-label IV ketamine is generally not covered by most insurance plans. Allay Health & Wellness accepts Medicare, Cigna, UnitedHealthcare, and Aetna for eligible services. Our team verifies available benefits and provides anticipated cost information before sessions are scheduled. Coverage varies by plan and is never guaranteed.
5. Do I need to stop seeing my rheumatologist?
   No. Arthritis pain ketamine therapy does not replace ongoing care from your rheumatologist, orthopedic specialist, or other treating providers. Continued management of the underlying arthritis remains important. Allay Health & Wellness can coordinate with your existing clinicians when appropriate so infusion treatment, if recommended, remains part of a broader care plan.

Schedule a Consultation for Arthritis Pain Ketamine Therapy

If established arthritis treatments have not provided adequate pain relief, Allay Health & Wellness is available to discuss whether arthritis pain ketamine therapy may have a place in your broader care plan. Our clinical team reviews your arthritis diagnosis, current disease management, previous pain treatments, medications, and overall health before making any recommendation. We also explain the off-label status of IV ketamine, available evidence, potential risks, and treatment limitations so you can make an informed decision.

Patients who want to understand the evidence behind treatment can review the peer-reviewed research that informs our clinical approach and learn more about the credentials of the Allay Health & Wellness clinical team. Because persistent arthritis pain can involve different pain mechanisms, our broader approach to chronic pain may also be relevant when determining appropriate next steps. Allay Health & Wellness treats adults aged 18 and older exclusively.

Address: 11000 Prosperity Farms Rd, Suite 101, Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444

Contact Allay Health & Wellness to schedule a consultation and discuss whether further evaluation for arthritis pain ketamine therapy may be appropriate.

Medical Disclaimer: This content is educational only and not a substitute for professional medical advice. IV ketamine for arthritis pain is an off-label use, not FDA-approved for arthritis or any pain condition. Spravato is not approved for pain. First-line arthritis treatments should be completed before off-label options are considered. Evidence for ketamine in arthritis pain is mechanistic and extrapolated from broader centralized pain literature. Individual outcomes vary and are never guaranteed. Allay treats adults 18 and older.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness